A Phase 3 interventional study of Sativex and GW-2000-02 in Pain and Cancer, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.
Among the 17 studies testing nabiximols in Pain, this one is the 16th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 3rd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2002.
This study's enrollment of 43 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 246 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 17 have an industry lead sponsor. The 3 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
20 studies in Pain by Jazz Pharmaceuticals: none open now, none under way, none of them phase 3. Of 20 finished, 20 (100%) have results posted.
Among the 20 studies in Pain by Jazz Pharmaceuticals, this one is the 19th largest by enrollment, is one of 6 that started in 2002, is one of 18 in phase 3, and was the 7th registered.
Jazz Pharmaceuticals’s Pain studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing nabiximols in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jazz Pharmaceuticals’s 20 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.
Subjects who have previously participated in GWCA0101, a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® (containing delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) and GW-2000-02 (containing THC alone) in subjects with cancer-related pain are screened, and if eligible begin dosing with open-label Sativex®. They are allowed to self-titrate their study medication to symptom resolution or maximum tolerated/allowable dose of 130 mg THC and 120 mg CBD and have the opportunity to request a change from Sativex® to GW-2000-02 if they or the investigator consider their response less than optimal. Subjects are reviewed for tolerability and evidence of clinical benefit at 7-10 days after Visit 1 and then every four weeks. Continuation within the study is conditional on satisfactory reports of tolerability, efficacy and dosing regime.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active treatment
Drug: Sativex
Active treatment
Drug: GW-2000-02
Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
Also known as: GW-1000-02
Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
The Incidence of Adverse Events as a Measure of Subject Safety
The number of subjects who experienced an adverse event in this study is presented.
Time frame: 0 - 657 days
Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment
The Brief Pain Inventory (Short Form) is a 14-item questionnaire that asks subjects to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items (range 0-10). The minimum value is zero and maximum is 10. A negative value indicates an improvement in score from baseline. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of the mean Brief Pain Inventory (Short Form) score was only carried out when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.
Time frame: 0 - 657 days
Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment
The EORTC Quality of Life-C30 Health Status visual analogue scale was a self-reported score where subjects rated their health state from: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score from baseline indicates an improvement in condition. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of mean EORTC Quality of Life-C30 Health Status scores was only produced when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.
Time frame: 0 - 657 days
The first subject was recruited on the 30th April 2002
| Milestone | Sativex | THC Alone |
|---|---|---|
| Started | 39 | 4 |
| Completed | 0 | 1 |
| Not completed | 39 | 3 |
| Withdrew: Adverse event | 23 | 1 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Pain under control | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Patient died | 1 | 0 |
| Withdrew: Patient unable to comply with diaries | 1 | 0 |
| Withdrew: Patient feels unable to take medication | 0 | 1 |
The number of subjects who experienced an adverse event in this study is presented.
| participants | Sativex | THC Alone |
|---|---|---|
| The Incidence of Adverse Events as a Measure of Subject Safety | 37 | 4 |
The Brief Pain Inventory (Short Form) is a 14-item questionnaire that asks subjects to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items (range 0-10). The minimum value is zero and maximum is 10. A negative value indicates an improvement in score from baseline. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of the mean Brief Pain Inventory (Short Form) score was only carried out when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.
| units on a scale | Sativex | THC Alone |
|---|---|---|
| Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment | -0.53 ± 1.28 | — |
The EORTC Quality of Life-C30 Health Status visual analogue scale was a self-reported score where subjects rated their health state from: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score from baseline indicates an improvement in condition. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of mean EORTC Quality of Life-C30 Health Status scores was only produced when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.
| units on a scale | Sativex | THC Alone |
|---|---|---|
| Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment | -2.0 ± 28.34 | — |
Collected over All adverse events (AEs) occurring from the time of consent to post study follow up (2 - 521 days) were collected. All deaths and serious adverse events (SAEs) occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sativex | — | 20/39 (51.3%) | 37/39 (94.9%) |
| THC Alone | — | 1/4 (25%) | 4/4 (100%) |
| Event | Sativex | THC Alone |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/39 | 1/4 |
| HaematemesisGastrointestinal disorders | 2/39 | 0/4 |
| ConfusionPsychiatric disorders | 2/39 | 0/4 |
| Anaemia NOS aggravatedBlood and lymphatic system disorders | 1/39 | 0/4 |
| Atrial fibrillationCardiac disorders | 1/39 | 0/4 |
| Diarrhoea NOSGastrointestinal disorders | 1/39 | 0/4 |
| Intestinal obstruction NOSGastrointestinal disorders | 1/39 | 0/4 |
| NauseaGastrointestinal disorders | 1/39 | 0/4 |
| Vomiting NOSGastrointestinal disorders | 1/39 | 0/4 |
| General physical health deteriorationGeneral disorders | 1/39 | 0/4 |
| Event | Sativex | THC Alone |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/39 | 1/4 |
| NauseaGastrointestinal disorders | 10/39 | 0/4 |
| VomitingGastrointestinal disorders | 10/39 | 1/4 |
| DizzinessNervous system disorders | 8/39 | 1/4 |
| HeadacheNervous system disorders | 2/39 | 1/4 |
| Memory impairmentNervous system disorders | 0/39 | 1/4 |
| ConfusionPsychiatric disorders | 7/39 | 1/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/39 | 1/4 |
| CholelithiasisHepatobiliary disorders | 0/39 | 1/4 |
| CellulitisInfections and infestations | 0/39 | 1/4 |
| Age, Categorical(Participants) | Sativex | THC Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 4 | 33 |
| >=65 years | 10 | 0 | 10 |
| Age, Continuous(years) | Sativex | THC Alone | Total |
|---|---|---|---|
| Mean | 57.5 ± 13.5 | 58.6 ± 6.28 | 57.6 ± 12.94 |
| Sex: Female, Male(Participants) | Sativex | THC Alone | Total |
|---|---|---|---|
| Female | 16 | 3 | 19 |
| Male | 23 | 1 | 24 |
| Region of Enrollment(participants) | Sativex | THC Alone | Total |
|---|---|---|---|
| United Kingdom | 31 | 3 | 34 |
| Belgium | 8 | 1 | 9 |
The record gives a start of Apr 2002, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 6 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nabiximols